288 filings
8-K
AXSM
Axsome Therapeutics Inc
1 Apr 24
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
8:27am
8-K
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
9:06am
8-K
AXSM
Axsome Therapeutics Inc
25 Mar 24
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
9:02am
8-K
AXSM
Axsome Therapeutics Inc
19 Mar 24
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
7:06am
10-K
2023 FY
AXSM
Axsome Therapeutics Inc
Annual report
23 Feb 24
8:10am
8-K
sgm8s
20 Feb 24
Corporate Presentation February 2024
4:30pm
8-K
528v h8mzsz5i5h7u
20 Feb 24
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:05am
8-K
mpr83wbt ie2eiq65
8 Jan 24
Corporate Presentation January 2024
7:10am
8-K
7rfnjhq62rqfpp6e92w
4 Jan 24
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
7:11am
8-K
mxo1gjvp3 aan
7 Dec 23
Other Events
4:05pm
8-K
wpw02clx
6 Nov 23
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
sw0k00d5j2fhl
11 Oct 23
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
5:03pm
8-K
u0eoh dnlo3g
15 Aug 23
Corporate Presentation August 2023
7:45am
8-K
fnkkmwkja yt5xg
7 Aug 23
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:02pm
8-K
2x8vfsn9buuqd0av
4 Aug 23
Other Events
4:49pm
8-K
ksmypipd0o8x3mho7e
7 Jul 23
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
8:21am
8-K
0h4 b1ybz6mbelloq0
30 Jun 23
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
4:05pm
424B5
l4w 8r2fh5ojhevpkx9h
28 Jun 23
Prospectus supplement for primary offering
8:16pm